DMAA
DMAA
NASDAQ · N/A

Drugs Made In America Acquis

$10.44
+0.01 (+0.10%)
As of Feb 8, 1:56 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 219.69M 205.61M 216.54M
Net Income 25.03M 23.39M 21.58M
EPS
Profit Margin 11.4% 11.4% 10.0%
Rev Growth -5.7% -2.0% +21.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 120.38M 114.41M 149.81M
Total Equity 137.89M 132.67M 131.31M
D/E Ratio 0.87 0.86 1.14
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 37.03M 38.19M 42.37M
Free Cash Flow 19.51M 14.22M 14.32M